The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable buzz within the medical community. This novel dual GIP and GLP-1 target medication suggests to offer impressive improvements in fat shedding compared to previous therapies. Early clinical trials have demonstrated su